|
Malignant mesothelioma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, biallelic NF2 gene inactivation is one of the most common mutations associated with the development of malignant mesothelioma (MM), a highly fatal malignancy that arises in the pleura and less frequently in the pericardium, peritoneum, and tunica vaginalis.
|
31567203 |
2020 |
|
Malignant mesothelioma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
MM is a very aggressive tumor associated with asbestos exposure, and genetic alterations in <i>NF2</i> that abrogate merlin's functional activity are found in about 40% of MMs, indicating the importance of <i>NF2</i> inactivation in MM development and progression.
|
29587439 |
2018 |
|
Malignant mesothelioma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).
|
29112861 |
2017 |
|
Malignant mesothelioma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
|
26928227 |
2016 |
|
Malignant mesothelioma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice.
|
26678224 |
2016 |
|
Malignant mesothelioma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
|
26463840 |
2016 |
|
Malignant mesothelioma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
|
23435014 |
2013 |
|
Malignant mesothelioma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Nearly 75% of MM cases have inactivating mutations in the NF2 (neurofibromatosis type 2; Merlin) gene or in downstream signaling molecules of the Hippo signaling cascade, which negatively regulates the transcription factor Yes-associated protein (YAP).
|
22329991 |
2012 |
|
Malignant mesothelioma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the Merlin-Hippo signaling cascade is one of the frequent and key events of MM cell development and/or progression.
|
21615608 |
2011 |
|
Malignant mesothelioma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Analysis of a panel of malignant mesothelioma cell lines reveals a strong correlation between loss of merlin and activation of mTORC1.
|
19451229 |
2009 |
|
Malignant mesothelioma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these findings suggest that merlin inactivation is a critical step in MM pathogenesis and is related, at least in part, with upregulation of FAK activity.
|
16652148 |
2006 |
|
Malignant mesothelioma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Inactivating mutations of the neurofibromatosis type 2 (NF2) tumor suppressor gene merlin have been described in nearly 60% of primary malignant mesothelioma and in approximately 20% of the mesothelioma cell lines.
|
12673723 |
2003 |
|
Malignant mesothelioma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
To study if LOH of the NF2 gene is a consistent feature in MM, we performed a more detailed analysis of chromosome 22q that included a NF2 marker (NF2CA3).
|
12168054 |
2003 |
|
Malignant mesothelioma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Consequently, the disruptions due to merlin inactivation in the progression of malignant mesothelioma may represent a tumor suppressor role operating by a different pathway than that in schwannoma or meningioma.
|
10214350 |
1999 |